Allogeneic NK Cells with a Bispecific Innate Cell Engager in Refractory Relapsed Lymphoma: A Phase 1 Trial

Researchers studied cord-blood-derived cytokine-preactivated and expanded NK cells precomplexed with AFM13 in patients with CD30⁺ lymphoma refractory to brentuximab vedotin and checkpoint inhibitors.